LeMaitre Vascular (LMAT) Earnings Put Its Valuation Narrative Back In Focus
Why LeMaitre Vascular’s Latest Earnings Caught Attention
LeMaitre Vascular (LMAT) drew fresh attention after third quarter 2026 results showed higher sales alongside lower quarterly net income and earnings per share, while the nine month figures pointed to higher revenue and profit.
LeMaitre Vascular’s latest update landed alongside a sharp 1 day share price return of 9.08% to US$87.92. This capped a 30 day share price return of 11.22% and a three year total shareholder return of 85.14%, which contrasts with a far more muted 1 year total shareholder return of 3.75%, as recent momentum has picked up after a cooler stretch.
Scan how LeMaitre Vascular compares to other medical stocks showing resilient earnings trends by reviewing our curated 31 resilient stocks with low risk scores in the same vein of quality and stability.
After a 9% one day jump and a three year return above 80%, LeMaitre Vascular now trades between an analyst target of US$107 and an implied intrinsic discount of about 27%. Which end of that range appears closer to fair value?
Most Popular Narrative: 18% Undervalued
LeMaitre Vascular’s most followed valuation story puts fair value at $107, comfortably above the last close of $87.92. This frames the recent rally as only part of the move implied by that view.
The current valuation implies the share price does not fully reflect the view that LeMaitre Vascular may be undervalued and that its cash generation, capital returns and growth projects could support a stronger equity narrative.
See why 6 investors see LeMaitre Vascular as 18% undervalued.
Result: Fair Value of $107 (UNDERVALUED)
Still, the LeMaitre Vascular story depends on clean regulatory audits and smoother tissue supply, since additional quality findings or prolonged constraints could pressure margins and guidance again.
Find out about the key risks to this LeMaitre Vascular narrative.
Another View: Multiples Paint A Richer Price Tag For LeMaitre Vascular
The story on LeMaitre Vascular shifts once the share price is compared to earnings. The stock trades on a P/E of 30.6x, which is higher than the US Medical Equipment industry at 23.9x and above a fair ratio of 23.6x, even though it sits slightly below the peer average of 32.1x.
That mix of richer pricing versus the wider sector, but only modestly cheaper than peers, points to limited margin for error if growth or margins undershoot expectations, especially when our own cash flow work suggests less upside than the analyst target implies.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment split between undervalued fair value models and richer P/E signals, your own read matters more than any single framework. Act quickly by reviewing the 2 key rewards.
Looking For More Investment Ideas Beyond LeMaitre Vascular?
If LeMaitre Vascular has your attention, do not stop here. Broaden your watchlist with other clear ideas that match different goals and risk levels.
- Target high potential turnarounds by scanning the 7 elite penny stocks with strong financials that already show stronger financial foundations than typical speculative trades.
- Zero in on quality at a discount by reviewing the 34 high quality undervalued stocks that combine solid fundamentals with prices that still trail underlying business strength.
- Build a sturdier core portfolio by filtering for a list of solid balance sheet and fundamentals (25 results) before the crowd focuses on these stronger financial structures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com